...
首页> 外文期刊>Scientific reports. >MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer
【24h】

MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer

机译:MicroRNA Let-7g充当肿瘤抑制和预测生物标志物,用于在人上皮卵巢癌中的化学抑制剂

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Remarkable deregulation of microRNAs has been demonstrated in epithelial ovarian cancer (EOC). In particular, some of the let-7 miRNA family members have been proposed as tumor suppressors. Here, we explored the functional roles of let-7g in EOC. The ectopic overexpression of let-7g in OVCAR3 and HEY-A8 EOC cells induced i) a down-regulation of c-Myc and cyclin-D2 thus promoting cell cycle arrest, ii) a reduction of Vimentin, Snail and Slug thus counteracting the progression of epithelial to mesenchymal transition, iii) a chemosensitization to cis-platinum treatment. Next, analysis of human EOC tissues revealed that let-7g expression was significantly reduced in tumor tissue specimens of patients with EOC compared to their non-tumor counterparts (p?=?0.0002). Notably, low let-7g tissue levels were significantly associated with acquired chemoresistance of patients with late-stage of EOC (n?=?17, p?=?0.03194). This finding was further validated in the serum samples collected from the same cohort of patients (n?=?17, p?=?0.003). To conclude, we demonstrate that let-7g acts as tumor suppressor and might be used to disable EOC tumor progression and chemoresistance to cis-platinum-based chemotherapy. Furthermore, we propose that decreased expression of let-7g could serve as a tissue and serum biomarker able to predict the chemo-resistant features of EOC patients.
机译:在上皮细胞卵巢癌(EOC)中已经证明了微小RNA的显着放松管制。特别是,已经提出了一些Let-7 miRNA系列成员作为肿瘤抑制剂。在这里,我们探讨了Let-7G在EOC的功能角色。在ovcar3和hey-a8 eoc细胞中诱导oOp-7g的异位过度表达诱导Ⅰ)促进C-myc和cyclin-d2的下调,从而促进细胞循环骤停,ii)减少了平方,蜗牛和slug的减少,从而抵消了进展上皮对间充质转换,III)对顺式铂治疗的化学敏化。接下来,人们EOC组织的分析表明,与非肿瘤对应物相比,EOC患者的肿瘤组织标本中,Let-7G表达显着降低了(P?= 0.0002)。值得注意的是,低let-7g组织水平与患者的后期患者的患者的化学抑制有显着相关(n?= 17,p?= 0.03194)。在从同一患者队列收集的血清样本中进一步验证了该发现(n?= 17,p?= 0.003)。为了得出结论,我们证明Let-7G充当肿瘤抑制剂,可用于禁用基于CIS-铂的化学疗法的EOC肿瘤进展和化学性。此外,我们提出的是,Let-7g的表达降低可以用作能够预测EOC患者的化学抗性特征的组织和血清生物标志物。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号